GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clementia Pharmaceuticals Inc (NAS:CMTA) » Definitions » Net Interest Income (for Banks)

Clementia Pharmaceuticals (Clementia Pharmaceuticals) Net Interest Income (for Banks)


View and export this data going back to 2017. Start your Free Trial

What is Clementia Pharmaceuticals Net Interest Income (for Banks)?

Net Interest Income only applies to banks.


Clementia Pharmaceuticals (Clementia Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
4150 St Catherine Street West, Suite 550, Montreal, QC, CAN, H3Z 2Y5
Clementia Pharmaceuticals Inc is a clinical stage biopharmaceutical company. It is developing disease-modifying treatments for patients suffering from debilitating bone and other diseases with high unmet medical need. The company's lead product candidate, palovarotene, is an oral small molecule that has shown potent activity in preventing abnormal new bone formation as well as fibrosis in a variety of tissues. Clementia is developing palovarotene for the treatment of Fibrodysplasia Ossificans Progressiva (FOP) and Multiple Osteochondroma (MO). It believes that if approved in FOP or MO, palovarotene could become the standard of care in either or both of these indications.